openPR Logo
Press release

Hepatocellular Carcinoma Drugs Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends | AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation

02-20-2024 11:06 AM CET | Health & Medicine

Press release from: The Business Research Company

Hepatocellular Carcinoma Drugs Global Market Report

Hepatocellular Carcinoma Drugs Global Market Report

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Hepatocellular Carcinoma Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives..

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access.. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp

Market Segmentation:
The hepatocellular carcinoma drugs market covered in this report is segmented -

1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Major Driver - Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market
The rise in the occurrence of hepatocellular carcinoma is expected to propel the growth of the hepatocellular carcinoma drug market over the coming years. Hepatocellular carcinoma (HCC) is a primary malignant disease of the liver and the most common form of liver cancer. Hepatocellular carcinoma starts with the main type of liver cells called hepatocyte cells. Most cases of HCC result from infection with hepatitis B or C, or cirrhosis. As the occurrence of hepatocellular carcinoma continuing to rise, it leads to an increased demand for effective hepatocellular carcinoma drugs to treat the disease. For instance, in 2023, according to the report published by the American Cancer Society, Inc, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the rise in the occurrence of hepatocellular carcinoma is driving the growth of the hepatocellular carcinoma drug market.

Competitive Landscape:
Major companies operating in the hepatocellular carcinoma drugs market report are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., GlaxoSmithKline, Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., TTY Biopharm Company Limited, Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

Top Trend - Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market
Major companies operating in the hepatocellular carcinoma drugs market are developing laboratory-produced molecule such as monoclonal antibodies (mAb) to meet larger customer bases, more sales, and increase revenue. A monoclonal antibody (mAb) is a laboratory-produced molecule that is engineered to mimic the immune system's ability to fight off harmful pathogens such as bacteria or viruses. For instance, in October 2022, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) Indicated for adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a distinctive human monoclonal antibody that effectively binds to the PD-L1 protein. By doing so, it hinders the interaction between PD-L1 and the PD-1 and CD80 proteins. This action disrupts the tumor's evasion of the immune system, releasing the inhibition of immune responses. As for Imjudo (tremelimumab), it stands out as a human monoclonal antibody designed to specifically target the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo works by blocking CTLA-4 activity, thereby promoting T-cell activation, priming the immune response against cancer, and fostering the death of cancer cells.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Hepatocellular Carcinoma Drugs Market Characteristics
3. Hepatocellular Carcinoma Drugs Market Trends And Strategies
4. Hepatocellular Carcinoma Drugs Market - Macro Economic Scenario
5. Hepatocellular Carcinoma Drugs Market Size And Growth
…..
27. Hepatocellular Carcinoma Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Drugs Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends | AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation here

News-ID: 3391159 • Views:

More Releases from The Business Research Company

Increasing Financial Fraud Incidents Propel Accounting and Auditing Market: A Key Catalyst Accelerating Accounting And Auditing Market Growth in 2025
Increasing Financial Fraud Incidents Propel Accounting and Auditing Market: A Ke …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Accounting And Auditing Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for accounting and auditing has seen a robust growth in the past few years. It is expected to increase from $222.35 billion in 2024 to $238.28 billion in 2025, reflecting a
Supply Chain Finance Market Expected to Achieve 8.6% CAGR by 2029: Growth Forecast Insights
Supply Chain Finance Market Expected to Achieve 8.6% CAGR by 2029: Growth Foreca …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Supply Chain Finance Market Size By 2025? The market size for supply chain finance has been experiencing a robust expansion in the past few years. The market, which is projected to escalate from $12.47 billion in 2024 to $13.42 billion in 2025, is expected to
Personal Loans Market on Track for Strong Growth, Estimated to Grow at 10.7% CAGR Through 2029
Personal Loans Market on Track for Strong Growth, Estimated to Grow at 10.7% CAG …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Personal Loans Market Through 2025? The personal loans industry has seen robust growth in recent years. The market size is projected to increase from $778.34 billion in 2024 to $854.94 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%.
Key Trends Reshaping the Mobile Wallet Market: Revolut Launches Innovative Mobile Wallet Feature to Enhance International Money Transfers Industry Transformation
Key Trends Reshaping the Mobile Wallet Market: Revolut Launches Innovative Mobil …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Mobile Wallet Market Size Growth Forecast: What to Expect by 2025? The scale of the mobile wallet market has experienced a monumental expansion in the past few years. Its morphology will evolve from $2109.19 billion in 2024 to a staggering $2754.87 billion by 2025, reflecting a compound annual growth

All 5 Releases


More Releases for Hepatocellular

Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period? The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Hepatocellular
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027 This latest report researches the industry structure, sales, revenue,
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market